GSK2831781: Phase I started

GlaxoSmithKline began a double-blind, placebo-controlled, U.K. Phase I trial to evaluate single ascending doses of 0.0003-5 mg/kg IV GSK2831781 in about 63 healthy volunteers and patients with plaque ...